SCHEMBL3015252

SCHEMBL3015252

COc1ccc(-c2csc(N3CCN(S(=O)(=O)c4cc(Br)ccc4OC)CC3)n2)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.52
KMT2A Q03164 3/20 0.50
MAPT P10636 2/20 0.49
RECQL P46063 2/20 0.49
USP2 O75604 2/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 4/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
KDM4E B2RXH2 1/20 0.48
REV1 Q9UBZ9 1/20 0.47
AR P10275 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP1A1 P04798 1/20 0.46
CYP1B1 Q16678 1/20 0.46
POLB P06746 1/20 0.45
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3654299 0.97 REV1 (0.51) GAAKMT2AMAPTRECQLUSP2
SCHEMBL15671706 0.94 REV1 (0.54) GAAKMT2AMAPTRECQLUSP2
SCHEMBL3010901 0.93 KMT2A (0.57) GAAKMT2AMAPTRECQLUSP2
SCHEMBL3017824 0.91 MAPT (0.47) GAAKMT2AMAPTRECQLUSP2
SCHEMBL3019105 0.89 ALDH1A1 (0.52) KMT2AMAPTRECQLUSP2HSD17B10
SCHEMBL3009903 0.89 GAA (0.54) GAAKMT2AMAPTRECQLUSP2
SCHEMBL3011654 0.89 POLB (0.56) GAAKMT2AMAPTRECQLUSP2
SCHEMBL3016289 0.89 MAPT (0.59) KMT2AMAPTRECQLUSP2HSD17B10
SCHEMBL3011444 0.89 MAPT (0.53) GAAKMT2AMAPTRECQLUSP2
SCHEMBL3012956 0.87 MAPT (0.51) GAAKMT2AMAPTRECQLUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GAA 110/4885KMT2A 2680/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.